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Poes Pregnancy Increase Cardiac Risk for
QT1 Patients With the KCNQ1-A341V Mutation?
arshall J. Heradien, MD,* Althea Goosen, RN,† Lia Crotti, MD,‡ Glenda Durrheim, PHD,†
alerie Corfield, PHD,† Paul A. Brink, MD,* Peter J. Schwartz, MD, FACC*‡
tellenbosch, South Africa; and Pavia, Italy
OBJECTIVES The purpose of this study was to assess the pregnancy-related cardiovascular risk in LQT1
patients.
BACKGROUND Only 1 study addressed this issue in genotyped patients and reported that the highest risk is
for LQT2 patients.
METHODS This case-control study, performed in a cohort of patients from 22 families affected by LQT1
and all sharing the common KCNQ1-A341V mutation, involved 36 mutation carriers and 24
of their unaffected sisters for a total of 182 pregnancies.
RESULTS There were 3 (2.6%) cardiac events (2 cardiac arrests) in the 115 LQT1 pregnancies. Because they
occurred only among the 27 mothers with previous symptoms, all off-therapy, the risk for
symptomatic patients is 11%, but decreases to 0 in symptomatic patients treated with beta-
blockers. Carriers and control subjects did not differ for the incidence of miscarriage (10% vs.
15%). Cesarean sections (C-sections), elective or owing to fetal distress, were performed more
often in carriers than in non-carriers (27% vs. 14%). Beta-blocker therapy did not influence the
prevalence of fetal distress. Among the infants born to carriers, all those with fetal distress were
carriers of the A341V mutation (10 of 10, 100%). Among the offspring of the carriers, 48 of 92
(52%) were mutation carriers, and of those, 15% died suddenly at age 14  6 years.
CONCLUSIONS Women affected by the common KCNQ1-A341V mutation are at low risk for cardiac events
during pregnancy and without excess risk of miscarriage; their infants delivered by C-section
because of fetal distress are extremely likely to also be mutation carriers. Beta-blockers remain
recommended. These conclusions likely apply to most LQT1 patients. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.0602006;48:1410–5) © 2006 by the American College of Cardiology Foundation
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(ongenital long QT syndrome (LQTS) is associated with
rolongation of the QT interval on the electrocardiogram,
ecurrent syncope, and sudden cardiac death (1,2). Molec-
lar diagnosis has allowed identification of at least 6 genetic
ubgroups. The 3 major subtypes (LQT1, due to mutations
ffecting KCNQ1, the gene encoding the IKs current;
QT2, due to mutations affecting KCNH2, the gene
ncoding the IKr current; and LQT3, due to mutations on
CN5A, the gene encoding the cardiac sodium channel)
ave their own clinical profile, despite some overlap
3,4 – 6). This includes markedly different genotype-
henotype correlations (7), ranging from natural history (8)
o gene-specific triggers for cardiac events (9) and to
esponse to therapy (9–11). Patients with LQT1 experience
ost of their cardiac events during exercise, especially
wimming, or in condition of emotional stress, especially
ear (9). This is the consequence of the impairment in the
Ks current, which disrupts the normal ability to shorten
entricular repolarization during increases in sympathetic
ctivity and heart rate (9). Thus, any condition that aug-
ents sympathetic activity can favor the occurrence of
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Department of Cardiology, University of Pavia and IRCCS Policlinico S. Matteo,
avia, Italy. This work was supported by National Institutes of Health grant
L68880 and Italian Ministry of Foreign Affairs grant “Basi genetiche della morte
ardiaca improvvisa: identificazione dei geni modificatori della severità clinica della
indrome del QT lungo.”t
Manuscript received March 15, 2006; revised manuscript received April 21, 2006,
ccepted May 31, 2006.ife-threatening arrhythmias in LQT1 patients. The coun-
erpart of this concept is the efficacy in these patients of
nti-adrenergic therapy, either beta-blocker (B) therapy or
eft cardiac sympathetic denervation (9–12).
Pregnancy is associated with hormonal changes that
rime cardiac receptors for adrenaline and other sympatho-
imetic neurotransmitters (13), whereas labor is also asso-
iated with a hyperadrenergic state due to pain, anxiety, and
ear (14,15). This physiological background justifies con-
erns for additional risk of cardiac events in LQT1 pregnant
omen. An important and negative consequence of these
oncerns is that many women affected by LQTS do not dare
o become pregnant or do so with fear.
However, except for 1 systematic study (16), the possibility
f an increased risk during pregnancy for LQTS-affected
others has been discussed only in isolated case reports
17–20). Rashba et al. (16) reported that the postpartum
nterval, specifically, was associated with a significant increase
n risk for cardiac events among LQTS patients. However, an
mportant limitation of that study—in light of the new
nowledge concerning the different genotypes—was that it did
ot distinguish between the different LQTS subgroups. In the
nly study involving genotyped patients, Khositseth et al. (21)
uggested that most of the cardiac events associated with
regnancy occur in LQT2 patients.
We have identified numerous South African families
f Afrikaner descent who harbor the same mutation
KCNQ1-A341V) due to a founder gene effect (22,23). In
his rather unique population we have retrospectively inves-
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October 3, 2006:1410–5 LQT1 and Pregnancyigated the outcome of pregnancies to assess cardiovascular
isk for both mothers and their infants.
The A341V represents a hot spot, because it has been
ound by investigators in Europe, America, and Asia.
oreover, we have demonstrated that this mutation is
ssociated with an unusually high clinical severity (23). This
uggests but does not prove that A341V might represent the
end-of-the-spectrum” and that it could be used to draw
areful inferences on the “worst case scenario” for LQT1
atients.
ETHODS
outh African LQT1 female carriers of the KCNQ1-
341V mutation, who were 20 years or older at the
ommencement of the study, were identified from our
QTS database. They were all contacted by telephone and
sked whether they would participate in the current study.
naffected sisters of affected women who agreed to answer
he same questions served as control subjects. The Univer-
ity of Stellenbosch Ethics Committee approved the study.
Each consenting subject received a self-administered,
elf-reported written questionnaire that contained questions
elating to the age at the time of her first and last syncope
ttack, the number of successful pregnancies, the birth-
eight of the babies, the number of abortions or stillbirths,
nd whether they had received any form of anti-adrenergic
herapy, such as beta-adrenergic blockers or left cardiac
ympathetic denervation during pregnancy or in the peri-
artum periods (defined as 40 weeks before and after
regnancy). Syncope was defined as complete loss of con-
ciousness resulting in loss of postural tone and lasting for
1 min. Aborted cardiac arrest refers to subjects who
eported having received cardiopulmonary resuscitation or
lectrical defibrillation.
All data reported in the questionnaire were subsequently
erified by telephone with the mothers on 2 different
Abbreviations and Acronyms
C-section  cesarean section
ECG  electrocardiogram/electrocardiography
LQTS  long QT syndrome
LQT1  LQT1 variant of LQTS
B  beta-blocker(s)
Table 1. Characteristics of Pregnancies of Carr
Non-Carriers
(n  24)
QTc (ms) 414  18*
Pregnancies 67
Live births 57/67 (85%)
Miscarriages 10/67 (15%)
C-sections (% of live births) 8/57 (14%)
Fetal distress (% of C-sections) 2/8 (25%)*p  0.0001 (unpaired t test); †p  0.001 (Fisher exact test).
B  beta-blocker therapy; B  without beta-blocker theccasions. Because the pregnancies occurred over a period of
6 years, it was possible to have information from general
ractitioners, obstetricians, pediatricians, or from the vari-
us hospitals only for the more recent ones and in most of
he cases of fetal distress.
The mutation-carrier status of individuals born to the
others who took part in the survey was determined from
ur database. The QT intervals were measured in standard
ead II of the electrocardiogram (ECG) and were corrected
or heart rate (QTc).
tatistical analysis. Differences among groups were ana-
yzed by using the t test for unpaired data, the chi-square
est, and the Fisher exact test (Prism software, version 3.02;
raphpad, San Diego, California), as appropriate. Data are
resented as mean values  1 SD. A p value 0.05 was
onsidered significant.
ESULTS
e identified and contacted 39 mutation carriers with
revious pregnancies and 26 control subjects. Of these, 36
92%) and 24 (92%), respectively, answered the question-
aire (Table 1). None of the non-responders died during/
fter pregnancy. The mean QTc interval of the mutation
arriers (508  59 ms, n  36) was markedly longer (p 
.0001) compared with that of the non-carriers (413  16
s, n  24). Importantly, of the 36 LQTS-affected moth-
rs, 27 (75%) had had cardiac events (7 had an aborted
ardiac arrest and 20 had syncope). The mean age at the first
nd last reported cardiac event among the 27 symptomatic
utation carriers was 9.8 (range 2 to 18) and 29.6 (range 14
o 55) years, respectively.
The mean ages at first and last pregnancy were, respec-
ively, 24 4 and 32 5 years among mutation carriers and
4  4 and 31  5 years among non-mutation carriers.
eri-partum syncope or cardiac arrest. As expected, there
ere no cardiac events among the control subjects. This was
ot the case among the LQTS mutation carriers. There
ere no peri-partum maternal deaths, but 3 cardiac events
1 syncope and 2 aborted cardiac arrests) did occur among
he carriers. The actual risk for the mothers during each
ull-term pregnancy was low, because there was 1 event
1/102 1%) during pregnancy and 2 (2/102 2%) within
he first 9 months after delivery. However, a different
attern emerged when the risk for the individual mothers
ersus Non-Carrier Mothers
ll Carriers
(n  36)
Carriers B
(n  8)
Carriers B
(n  28)
08  58* 534  78 501  53
115 15 100
2/115 (89%) 13/15 (87%) 89/100 (89%)
2/115 (10%) 2/15 (13%) 10/100 (10%)
8/102 (27%) 9/13 (69%)† 19/89 (21%)†
10/28 (36%) 3/9 (33%) 7/19 (37%)ier V
A
5
10
1
2rapy; C-section  cesarean section; QTc  corrected QT.
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LQT1 and Pregnancy October 3, 2006:1410–5as examined on the basis of their previous clinical history
nd medication.
The 9 carriers who were asymptomatic before pregnancy
ad no cardiac events at all during their 30 pregnancies
mean 3.3/person). By contrast, among the 27 mutation
arriers who had cardiac symptoms before becoming preg-
ant, 3 (11%) suffered cardiac events during or after their 85
regnancies (mean 3.1/person). One carrier had a cardiac
rrest during pregnancy (1 of 27  3.7%), whereas 2
eported 1 syncope and 1 cardiac arrest in the post-partum
eriod (2 of 27  7.4%). No ECG was taken during these
vents, and therefore there is no documentation of the
rrhythmias. None of these 3 patients were receiving B
herapy during pregnancy or in the post-partum period.
one of the 3 cardiac events occurred during the first
regnancy. The 2 patients symptomatic after pregnancy
uffered their cardiac events 3 and 4 months after delivery.
bstetrical and infant data. A total of 182 pregnancies
ere reported in the 60 women (36 carriers and 24 of their
naffected sisters) (Table 1). Of these, the mutation carriers
eported 115 pregnancies, of which 102 were live, full-term
38 to 40 weeks gestation) births; they occurred during a
eriod of time spanning 56 years. Because diagnosis and
herefore treatment of LQTS were rare in South Africa
efore 1975, most analyses on the differences between
atients taking B and those not taking B were focused on
he pregnancies ending from 1975 onward (Table 2). The
ncidence of miscarriage was similar in the 2 groups, because
t was 10% (12 of 115) in pregnancies experienced by
arriers and 15% (10 of 67) in the control group (p  NS).
mong carriers there was also a stillbirth. With the excep-
ion of the latter, all the unsuccessful pregnancies ended in
pontaneous abortion within the first 6 weeks of gestation.
here were no reported therapeutic or elective abortions.
ifteen pregnancies were completed under B, whereas 100
ere in untreated carriers; the percentage of miscarriages is
imilar in both groups (13% and 10%, respectively).
Cesarean sections, all performed under general anesthesia
nd without any complication, were more common in
QTS mothers compared with control subjects (28 of 102,
7% vs. 8 of 57, 14%; p  0.053) and among mutation
arriers treated with B compared with those not receiving
herapy (9 of 13, 69% vs. 19 of 89, 21%; p  0.001).
owever, this finding was influenced by the fact that until
he 1970s most deliveries occurred at home and C-sections
ere limited to special cases. Among pregnancies after
Table 2. Characteristics of Pregnancies After 1
Total live births
Live births post 1975 (% of all live births)
C-sections post 1975 (% of all C-sections)
C-sections post 1975 (% of live births after 1975)
Fetal distress (% live births after 1975)
Fetal distress (% of C-sections after 1975)Abbreviations as in Table 1.975, the prevalence of C-sections in mutation carriers
reated or not with B was not significantly different (9 of
3, 69% vs. 18 of 36, 50%; p  0.2).
Fetal distress was the cause of C-section in 12 of 36
33%) pregnancies: in 10 of 28 (36%) LQTS mothers and in
of 8 (25%) control subjects (NS). Because B could
acilitate fetal bradycardia, we considered the possibility that
hey could have caused a greater number of C-sections due
o fetal distress among mothers in therapy. However, there
as no difference between the prevalence of fetal distress
mong carriers receiving B therapy and those not receiving
B therapy, both considering all of the pregnancies (33% vs.
7%, p  NS) and only those after 1975 (33% vs. 39%, p 
S). This rules out B as a direct cause for fetal distress.
Among the mutation carriers, the probability of the
ccurrence of fetal distress was independent of both QTc
uration and age at first cardiac event, even though a
onsignificant trend existed for QTc duration to be longer
511  49 vs. 488  53 ms, p  NS) and for cardiac events
o occur earlier (4.4 vs. 6.1 years, p  NS) among the
others destined to show signs of fetal distress.
Interestingly and importantly, among the infants from
QTS mothers, all those (10 of 10, 100%) who had suffered
etal distress were subsequently found to be mutation
arriers. By contrast, only 38 of 92 (41%) infants born
ithout fetal distress were mutation carriers. This represents
significantly different (p 0.001) probability to be affected
y LQTS according to the presence of fetal distress.
Apgar score was available in 6 of 10 babies born with fetal
istress, and the mean value was 8 of 10 at 1 min after birth
nd 10 of 10 at 5 min after birth. In 3 of the 4 who had an
nknown Apgar score, mothers referred to a pink skin color
nd a good and strong cry. Mean birth weight was lower
mong babies born to mothers taking B (2.9  0.6 kg vs.
.3  0.6 kg, p  0.03). Mean gestational week was the
ame in the 2 groups (39  1 vs. 39  2).
Of the 102 full-term births in the LQTS group, 85 (83%)
nderwent molecular screening to determine their carrier
tatus, whereas 10 had not yet undergone genetic testing.
he remaining 7 children (7%), all untreated, died suddenly
t an average age of 14  6 years (range 3 to 21) and were
onsidered to be mutation carriers. Among those geno-
yped, 41 were mutation carriers for a total of 48 (41  7
udden deaths) of 92 tested (52%), whereas 44 (48%) were
ot. No information was available about the carrier/non-
arrier status of the 12 aborted fetuses and the stillbirth. In
arriers B Carriers B p Value
13 89
13/13 (100%) 36/89 (40%) 0.0001
9/9 (100%) 18/19 (95%) NS
9/13 (69%) 18/36 (50%) NS
3/13 (23%) 7/36 (19%) NS
3/9 (33%) 7/18 (39%) NS975
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October 3, 2006:1410–5 LQT1 and Pregnancyhis cohort of young individuals affected by LQT1, the
ncidence of sudden cardiac death was 15% (7 of 48).
ISCUSSION
his is the first report to provide comprehensive data
oncerning the risks and consequences of pregnancy for
omen affected by one of the most common mutations
ausing the LQT1 genetic subgroup of the LQTS
KCNQ1-A341V). The results of this case-control study
lso suggest rational strategies for the management of
regnant A341V-LQT1 women and their offspring.
The main findings were that A341V-LQT1 women are
t low risk for cardiac events during pregnancy and the 9
onths following delivery, that there is a trend for a higher
isk among those who already had cardiac events before
regnancy, that there is no excess risk for miscarriage, and
hat the infants delivered by C-section because of fetal
istress are extremely likely to also be mutation carriers.
Because the clinical manifestations of the A341V patients
re indistinguishable from those of the LQT1 group at
arge, with the exception of an apparent greater clinical
everity (23), it seems reasonable to expect that most of the
ndings reported here would also apply to most LQT1
omen. If anything, the risks associated with pregnancy in
QT1 women might be even lower than those observed in
he rather malignant A341V form of LQTS.
QTS and pregnancy-related cardiac events. Because
regnancy is an emotionally stressful period and the post-
artum period is associated with frequent sleep disruption, it
ad been presumed that patients affected by a disease such
s LQTS—in which stress plays a significant role for the
ccurrence of life-threatening arrhythmias (1,9,24)—would
e at increased risk during or after a pregnancy. This view
eemed to be confirmed by the study by Rashba et al. (16)
n which the post-partum period was associated with a
ignificant increase in risk for cardiac events. They studied
regnancies in 111 probands and compared them with 105
ffected (on the basis of a QTc duration 470 ms) family
embers and 134 unaffected family members. Probands,
ut not their affected family members, had a higher than
xpected incidence of cardiac events during the post-partum
eriod. Their conclusion was limited by the fact that the
ata were obtained in LQTS patients irrespective of their
enotype. Very recently, this limitation was partially over-
ome by Khositseth et al. (21), who observed that most of
he arrhythmic events related to pregnancy in LQTS pa-
ients occurred in the LQT2 subgroup. Our findings,
ndicating a low risk among LQT1 patients, support that
onclusion.
Because the present data demonstrate that A341V-
QT1 patients and probably most LQT1 patients with
ther mutations are at low risk for pregnancy-related cardiac
vents, it follows that the combined picture emerging by
lso using the data by Rashba et al. (16) and by Khositseth
t al. (21) is indeed pointing to a genotype-phenotype oifference such that this risk is relatively small for LQT1
atients and relatively large for LQT2 patients. No data are
s yet available on the smaller LQT3 subgroup.
mplications for the mothers. These data allow us to
eassure A341V-LQT1 women about the fact that they can
pproach pregnancy without undue anxiety. If they were
symptomatic before becoming pregnant, this risk is indeed
inimal; if they already suffered cardiac events, their risk of
recurrence is around 10%. It is quite reasonable to expect
hat B therapy—which is quite effective for LQT1 patients
7,9–11)—would further reduce or totally prevent arrhyth-
ic episodes. Actually, in our population none of the
reviously symptomatic patients experienced a cardiac event
hile receiving B therapy during or after pregnancy.
urrent knowledge, reinforced by the present data, indi-
ates that every A341V-LQT1 patient who becomes preg-
ant, if not already under treatment, should be started
n B.
The probability of a miscarriage is not different compared
ith control women and is similar to that of the general
opulation (25). Thus, there should be no specific fears for
his possibility.
The probability of a C-section is greater in mutation
arriers compared with control subjects and in mutation
arriers receiving B compared with those not receiving
herapy. The latter is simply owing to the pregnancies that
ook place before 1975, when LQTS was very seldom
iagnosed and treated and when C-sections were also
nusual. After 1975, rates of 69% (B therapy) and 50% (no
B therapy) are in line with South African private hospital
ractice of 65% (26). Even though B could facilitate fetal
radycardia, they did not increase the prevalence of fetal
istress. However, it is fair to say that it could be difficult to
uickly distinguish between a bradycardia due to LQTS and
true obstetrical event. In doubt, the performance of a
-section seems a safe choice.
Indeed, our data raise the possibility that many of the
-sections performed in LQTS mothers are not necessary,
ecause the fetal bradycardia—a major cause for the diag-
osis of fetal distress—might simply reflect the presence of
n infant affected by LQTS. This is supported by the fact
hat the Apgar score, when available, was normal in those
ffected babies born with a supposed fetal distress.
mplications for the infants. The transmission of the
utation to the infants of these 36 mutation carriers took
lace in 52% of cases, in accordance with autosomal dom-
nant Mendelian inheritance. This strongly suggests that,
ithin A341V-LQT1 patients, there is no excess loss of
ffected individuals either at conception, developmentally,
r anywhere else during the course of pregnancy. Indeed,
he abortion rate of 10% compares well with that of 15%
ithin the control group and South Africa in general (25)
nd allows the conclusion that infants conceived by A341V-
QT1 mothers do not have a higher risk of dying in uterus.
n contrast, the existing but largely anecdotal observations
f stillbirths due to LQTS (27–29) foster the concept that
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LQT1 and Pregnancy October 3, 2006:1410–5ithin the overall LQTS population, the prevalence of
tillbirths might be higher within the LQT2 and LQT3
ubgroups (30).
A practically important and unexpected observation was
hat within the group of affected mothers, all the infants
ith fetal distress were subsequently found to be mutation
arriers. Because the ECG during the first few days of life
ight show spurious QT prolongation even in normal
nfants (31,32) and because genetic testing can take weeks
r months (according to the knowledge of the mutation in
he mother), fetal distress might be a key for a very strong
uspicion that the newborn is indeed affected by LQTS.
his in turn will allow the institution of the appropriate
reventive strategies according to the guidelines of the
uropean Society of Cardiology (32).
Finally, the present data support the existing concept that
aternal B treatment has no negative consequences for the
nfant and its development. Indeed, it does not increase the
umber of miscarriages and, even though the birth weight
f these infants is lower than that of infants of LQTS
others not receiving therapy, a mean weight of 2.9 kg is
ot enough to justify concern.
enetic implications. The A341V is a relatively common
QT1 mutation and represents a mutational hotspot. It is
nproven but likely that the observations made in the
resent study can be largely extrapolated to the entire LQT1
opulation. Indeed, A341V patients have their cardiac
vents primarily during physical and emotional stress, espe-
ially swimming, as we have described for the LQT1
opulation (9); also, their T waves match the morphology
e had described for the LQT1 group (33), and they
espond very well to B, as do most LQT1 patients (11).
There is one potential difference between A341V and
ost LQT1 patients, but its nature is such that it does not
ffect the interpretation of the present results. Indeed, a
urprising observation was that 74% of these women muta-
ion carriers had cardiac events. This percentage of symp-
omatic patients is markedly higher than that reported in
ver 300 LQT1 patients (8) and, together with the 15%
ncidence of sudden death among the offspring of the
utation carriers, raises the intriguing possibility that
341V is a mutation of unusual severity. This is supported
y our recent analysis of a large group of LQT1 patients all
arrying the KCNQ1-A341V mutation (23).
onclusions. In conclusion, A341V-LQT1 women
hould approach pregnancy without fear. They should all be
reated with B. The presence of fetal bradycardia is more
ikely to reflect the presence of LQTS than true fetal
istress, and whenever fetal distress is diagnosed, it is quite
ikely that the infant will be a mutation carrier.
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